Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 17;17(6):e1009122.
doi: 10.1371/journal.pcbi.1009122. eCollection 2021 Jun.

Contact tracing efficiency, transmission heterogeneity, and accelerating COVID-19 epidemics

Affiliations

Contact tracing efficiency, transmission heterogeneity, and accelerating COVID-19 epidemics

Billy J Gardner et al. PLoS Comput Biol. .

Abstract

Simultaneously controlling COVID-19 epidemics and limiting economic and societal impacts presents a difficult challenge, especially with limited public health budgets. Testing, contact tracing, and isolating/quarantining is a key strategy that has been used to reduce transmission of SARS-CoV-2, the virus that causes COVID-19 and other pathogens. However, manual contact tracing is a time-consuming process and as case numbers increase a smaller fraction of cases' contacts can be traced, leading to additional virus spread. Delays between symptom onset and being tested (and receiving results), and a low fraction of symptomatic cases being tested and traced can also reduce the impact of contact tracing on transmission. We examined the relationship between increasing cases and delays and the pathogen reproductive number Rt, and the implications for infection dynamics using deterministic and stochastic compartmental models of SARS-CoV-2. We found that Rt increased sigmoidally with the number of cases due to decreasing contact tracing efficacy. This relationship results in accelerating epidemics because Rt initially increases, rather than declines, as infections increase. Shifting contact tracers from locations with high and low case burdens relative to capacity to locations with intermediate case burdens maximizes their impact in reducing Rt (but minimizing total infections may be more complicated). Contact tracing efficacy decreased sharply with increasing delays between symptom onset and tracing and with lower fraction of symptomatic infections being tested. Finally, testing and tracing reductions in Rt can sometimes greatly delay epidemics due to the highly heterogeneous transmission dynamics of SARS-CoV-2. These results demonstrate the importance of having an expandable or mobile team of contact tracers that can be used to control surges in cases. They also highlight the synergistic value of high capacity, easy access testing and rapid turn-around of testing results, and outreach efforts to encourage symptomatic cases to be tested immediately after symptom onset.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Pathogen reproductive number, Rt, plotted against the ratio of contacts needing tracing to contact tracing capacity for variable delays (1/τIs) of 1–5 and 10 days between case symptom onset and the start of contact tracing (including getting tested and receiving result).
With testing, but no contact tracing, Rt increases 35% from 1.7 to 2.3 as the delay 1/τIs increases from 1 to 5 days, which is evident in the y-axis difference between black and green curves in the upper right of the graph where new case burdens are so high contact tracing is ineffective. The delays (1/τIs) are indicated by the small numbers on each curve in the left of the plot. Curves are horizontal where capacity exceeds contacts needing tracing. The number of contacts per case, Ncpc, was 10.
Fig 2
Fig 2. Pathogen reproductive number, Rt, plotted against the number of cases per contact tracer calls per day, for four different numbers of contacts per case (5, 10, 20, 30; these reflect the range of contacts before and during restrictions on social gatherings [39,45,46]).
The number of contacts per case is indicated by the small numbers on each curve in the middle of the plot. The average delay between symptom onset and contact tracing (including getting tested and receiving result), 1/τIs, is set to 5 days; as a result, the green curve is identical to the green curve in Fig 1.
Fig 3
Fig 3. Reduced contact tracing efficiency with increasing cases leads to accelerating epidemics.
Top panels (A, B, C) show the number of susceptible, infected (latent, pre-symptomatic and symptomatic combined), and recovered individuals. Bottom panels (D, E, F) show the reproductive number, Rt, over time. Left most panels (A, D) show dynamics with no contact tracing but social distancing (κ = 0.58) set to give same initial R0 (1.35) as with contact tracing. Middle panels (B, E) show dynamics with effectively unlimited contact tracing (1500 contact tracers making 12 calls/day; 10 contacts per case) but no social distancing (κ = 1), with an identical value of R0 as in panels A, D. Right panels (C, F) show dynamics with the same parameter values as (B, E) except with limited contact tracing (15 contact tracers). R0 is the same value as in panels D and E (R0 = 1.35), but Rt increases as cases increase and contact tracing becomes inefficient, which overwhelms the decrease in the fraction of the population that is susceptible. In all panels, the delay from symptom onset to receiving test results, 1/τIs, is 5d. All populations start with 100,000 individuals. Note the identical epidemic sizes (final fraction susceptible 0.53) for panels A (social distancing) and B (effectively unlimited contact tracing), but much larger epidemic size for limited contact tracing in panel C (final fraction susceptible 0.14).
Fig 4
Fig 4. Variability in the timing and outcome of epidemics due to stochastic variation in individual transmission.
Lines show number of latently infected individuals in the E class over time for 1 year with moderate social distancing that reduces contact rates by 40% (κ = 0.6). Grey lines show runs from a single stochastic simulation and the black line shows the deterministic outcome. The fraction of epidemics that establish is the fraction of simulations where the maximum number of people infected at any time exceeds the starting number infected. The four scenarios shown include different starting numbers of latently infected individuals on day 0, E0 (A, C: 5; B, D: 50), and with (A, B) or without (C, D) contact tracing (CT) which lowered R0 from 1.57 to 1.33. The delay from symptom onset to testing and tracing 1/τIs was 10d. The modeled population of 100,000 people had 15 tracers making 12 calls/day, and each case had an average of 10 contacts which is intermediate between pre-lockdown and lockdown conditions; this scenario is the same as the yellow line in Fig 1.

Similar articles

Cited by

References

    1. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395(10225):689–97. doi: 10.1016/S0140-6736(20)30260-9 WOS:000516755200027. - DOI - PMC - PubMed
    1. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020;395(10231):1225–8. doi: 10.1016/S0140-6736(20)30627-9 WOS:000526814200032. - DOI - PMC - PubMed
    1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al.. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–+. doi: 10.1038/s41586-020-2012-7 WOS:000518098100001. - DOI - PMC - PubMed
    1. Zhu N, Zhang DY, Wang WL, Li XW, Yang B, Song JD, et al.. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. doi: 10.1056/NEJMoa2001017 WOS:000517119800008. - DOI - PMC - PubMed
    1. Brauner JM, Mindermann S, Sharma M, Johnston D, Salvatier J, Gavenčiak T, et al.. Inferring the effectiveness of government interventions against COVID-19. Science. 2021;371(6531):eabd9338. doi: 10.1126/science.abd9338 - DOI - PMC - PubMed

Publication types

Grants and funding

AMK received funding from National Science Foundation Grants DEB-1911853 and DEB-1717498 (www.NSF.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.